News from mylan inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

07:30 ET

Mylan Confirms First-to-File Patent Challenge Relating to BREVIBLOC®

Mylan Inc. (Nasdaq: MYL) today confirmed that it and several subsidiaries have been sued by Baxter International, Inc., Baxter Healthcare...

Nov 07, 2014, 08:00 ET
Mylan

Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors

Mylan Inc. (Nasdaq: MYL) today announced it has signed a multi-year strategic alliance agreement with Walt Disney Parks and Resorts to help...

Nov 05, 2014, 07:30 ET

Mylan Launches Generic Loestrin 24 Fe®

Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous...

Oct 30, 2014, 16:05 ET

Mylan Third Quarter 2014 Adjusted Diluted EPS Increases 41% to $1.16

 Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and nine months ended September 30, 2014. Third Quarter...

Oct 30, 2014, 12:48 ET

Mylan Launches Generic Viramune XR®

Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Nevirapine Extended-release tablets, 400 mg, which is the generic version of...

Oct 27, 2014, 12:34 ET
http://www.multivu.com/players/English/7160152-mylan-specialty-epipen4schools-program-anaphylaxis-preparedness/gallery/image/170fc165-1cf8-46bd-b606-c27e835d5e04.HR.jpg

EpiPen4Schools® Program Enhances Support of National Movement to Improve Anaphylaxis Preparedness and Access to Emergency Treatment in Schools

Mylan Specialty, the fully integrated specialty pharmaceutical business of Mylan Inc. (NASDAQ: MYL), today announced new EpiPen4Schools®...

Oct 06, 2014, 07:30 ET

Mylan Launches Generic Combivir®

 Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg, which is the...

Oct 03, 2014, 07:00 ET

Mylan Increases Third Quarter and Full Year 2014 Adjusted Diluted EPS Guidance Range

 Mylan Inc. (Nasdaq: MYL) today announced that it expects third quarter adjusted diluted earnings per share to be in the range of $1.12 to...

Sep 16, 2014, 07:30 ET
Mylan (PRNewsFoto/Mylan)

Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus® and Insulin Analog to Lantus®

 Mylan Inc. (Nasdaq: MYL), one of the world's leading global pharmaceutical companies, today announced it is initiating Phase III clinical...

Sep 15, 2014, 06:30 ET
Mylan (PRNewsFoto/Mylan)

Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi® (Sofosbuvir) and Single Tablet Regimen of Ledipasvir/Sofosbuvir, in Developing Countries

 Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences,...

Sep 10, 2014, 07:00 ET
Mylan (PRNewsFoto/Mylan)

Mylan to Acquire U.S. Rights to Arixtra® (fondaparinux sodium) Injection from Aspen

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Ireland Limited has entered into an agreement to acquire the U.S....

Sep 08, 2014, 07:00 ET
Mylan (PRNewsFoto/Mylan)

Court Grants Summary Judgment in Favor of Mylan and FDA Related to Generic Precedex™

 Mylan Inc. (Nasdaq: MYL) today commented on a ruling by the U.S. District Court for the District of Maryland related to its product,...

Sep 05, 2014, 07:30 ET
Mylan (PRNewsFoto/Mylan)

Mylan Launches Generic Boniva® Injection

Mylan Inc. (Nasdaq: MYL) today announced that it has launched Ibandronate Sodium Injection, 1 mg (base)/mL, packaged in 3 mg (base)/3 mL pre-filled...

Aug 28, 2014, 11:21 ET
Mylan (PRNewsFoto/Mylan)

Mylan's ANDA for Three Times Per Week Generic Copaxone® 40 mg/mL Accepted for Filing by FDA

 Mylan Inc. (Nasdaq: MYL) today announced that its abbreviated new drug application (ANDA) for a three times per week Glatiramer Acetate...

Aug 25, 2014, 08:01 ET

Ready2Go™ Draft Winners Join Pro Football MVP Adrian Peterson in Educational Video About Anaphylaxis Preparedness

Mylan Specialty, the fully integrated specialty pharmaceutical business of Mylan Inc. (NASDAQ: MYL), and pro football player and EpiPen®...

Aug 22, 2014, 07:30 ET

Mylan Launches First Generic Klor-Con® Extended-Release Tablets

 Mylan Inc. (Nasdaq: MYL) today announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750...

Aug 19, 2014, 11:42 ET
Mylan (PRNewsFoto/Mylan)

Mylan Launches Generic Precedex™ Injection - Another Key Product Approval

 Mylan Inc. (Nasdaq: MYL) announced that its business Mylan Institutional has launched Dexmedetomidine Hydrochloride Injection, 100 mcg...

Aug 11, 2014, 07:30 ET

Mylan Launches Generic Xeloda® Tablets

Mylan Inc. (Nasdaq: MYL) today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's...

Aug 07, 2014, 06:30 ET

Mylan Reports Second Quarter 2014 Adjusted Diluted EPS of $0.69, In Line With Guidance

Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and six months ended June 30, 2014. Second Quarter 2014...

Jul 23, 2014, 07:00 ET
Mylan (PRNewsFoto/Mylan)

Mylan Wins Motion for Temporary Restraining Order Against Apotex for Authorized Generic of Paxil® CR

Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of New Jersey granted its motion for a temporary restraining...